Mobile

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder DRAGON

Update Il y a 4 ans
Reference: EUCTR2005-002256-17

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the dose-response relationship of YM178-OCAS on efficacy in patients with OAB.

Inclusion criteria

  • Overactive Bladder

Links